Tech Company Financing Transactions

Aragon Pharmaceuticals Funding Round

Aragon Pharmaceuticals closed a $50 million Series D investment round on 9/26/2012. Investors included venBio, Aisling Capital and OrbiMed.

Transaction Overview

Company Name
Aragon Pharmaceuticals
Announced On
9/26/2012
Transaction Type
Venture Equity
Amount
$49,999,988
Round
Series D
Investors

venBio (Lead Investor) (Robert Adelman)

Aisling Capital (Brett Zbar)

OrbiMed (Carl Gordon)

The Column Group (Peter Svennilson)

Topspin Partners (Leo Guthart)

Proceeds Purpose
This financing combined with our raise earlier this year provides Aragon with the resources to advance our pipeline, including ARN-509 for which we just recently announced promising Phase II results in prostate cancer patients.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
12780 El Camino Real 301
San Diego, CA 92130
USA
Phone
(858) 369-7600
Website
www.aragonpharmaceuticals.com
Email Address
[email protected]
Overview
Aragon Pharmaceuticals is a San Diego based biopharmaceutical company focused on developing a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers.
Profile
Aragon Pharmaceuticals LinkedIn Company Profile
Social Media
Aragon Pharmaceuticals Company Twitter Account
Company News
Aragon Pharmaceuticals News
Facebook
Aragon Pharmaceuticals on Facebook
YouTube
Aragon Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Financial Officer
Paul Cleveland
  Paul Cleveland LinkedIn Profile  Paul Cleveland Twitter Account  Paul Cleveland News  Paul Cleveland on Facebook
Chief Medical Officer
Isan Chen
  Isan Chen LinkedIn Profile  Isan Chen Twitter Account  Isan Chen News  Isan Chen on Facebook
President
Richard Heyman
  Richard Heyman LinkedIn Profile  Richard Heyman Twitter Account  Richard Heyman News  Richard Heyman on Facebook
VP - Bus. Development
Angie You
  Angie You LinkedIn Profile  Angie You Twitter Account  Angie You News  Angie You on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/26/2012: V-Key venture capital transaction
Next: 9/27/2012: GraphDive venture capital transaction

 

Share this article

 

About Our VC Transactions Data

Our team works diligently to report on tech company VC transactions. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.